Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-NK-CD19 cells
- Development stage
- Unknown
- Lead developer
- Beijing Gaobo Boren Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CAR-NK-CD19 cells are an investigational chimeric antigen receptor (CAR) engineered natural killer (NK) cell therapy developed by Beijing Boren Hospital. These cells are designed to target and eliminate CD19-positive B-cell malignancies, including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL). Unlike CAR-T cell therapies, CAR-NK cells utilize natural killer cells as the effector platform, which may offer advantages such as a lower risk of cytokine release syndrome (CRS) and graft-versus-host disease (GvHD), as well as the potential for off-the-shelf use. The therapy involves the infusion of NK cells modified to express a CAR specific for the CD19 antigen, typically following a lymphodepletion regimen of fludarabine and cyclophosphamide.
- Other names
- Anti-CD19 CAR-NK cellsAnti-CD-19 CAR-NK cellsAnti-CD 19 CAR-NK cellsCD19-targeted CAR-NK cellsCD-19-targeted CAR-NK cellsCD 19-targeted CAR-NK cells
02
Targets
Beyond the preview
Go deeper on CAR-NK-CD19 cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-NK-CD19 cells.